Enveric Biosciences (NASDAQ:ENVB) Releases Earnings Results

Enveric Biosciences (NASDAQ:ENVB) issued its quarterly earnings results on Friday. The company reported ($0.57) earnings per share (EPS) for the quarter, Zacks reports.

Enveric Biosciences Stock Performance

NASDAQ ENVB traded down $0.01 during trading on Friday, hitting $1.51. 17,393 shares of the company’s stock traded hands, compared to its average volume of 1,248,426. The stock has a market capitalization of $6.79 million, a price-to-earnings ratio of -0.12 and a beta of 1.23. Enveric Biosciences has a 12-month low of $1.17 and a 12-month high of $13.25. The business has a 50 day moving average of $1.47 and a 200-day moving average of $1.90.

Wall Street Analyst Weigh In

A number of research firms recently commented on ENVB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enveric Biosciences in a report on Thursday, October 15th. Wall Street Zen raised Enveric Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc. is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and central nervous system disorders. The company’s research uses insights from cannabinoid science and psychedelic-inspired compounds to identify potential treatments for conditions with significant unmet medical needs. Enveric has developed a portfolio of proprietary drug candidates and intellectual property, including programs aimed at mental health conditions such as depression and other neurological disorders, as well as therapies intended to address cancer-related symptoms and supportive-care needs.